HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's Decisions On 'Article' As Dietary Or Drug Ingredient: Level Playing Field?

Executive Summary

FDA drug center could hold more sway over which ingredients are allowed for use in supplements than center regulating supplement industry, suggests CRN CEO Steve Mister at a recent regulatory conference. ODSP second-in-command Gregory Noonan allows that agency has “vague” rule for “article” used in a supplement or a drug.

You may also be interested in...



Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use

Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.

It’s Official: US Enforcement Discretion For NAC In Supplements, And Regulatory Options For FDA

Draft guidance states enforcement discretion allowing sales of N-acetyl-L-cysteine supplements which FDA in 2020 ordered firms to halt selling due to its use as a drug ingredient. However, NAC supplements, as they have remained since 2020, were available to US consumers when draft was published.

Red Yeast Rice History Offers Blueprint For Clearing CBD As Dietary Ingredient

Legal dispute between FDA and Pharmanex decided in 1999 could be precedent for using hemp-derived ingredients including CBD in supplements, even though CBD already has been authorized for clinical drug evaluation and for use in a drug, says attorney Miriam Guggenheim.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel